inhibitor)-on the cell-based assay. 4, 5 We found that U0126 and geldanamycin preferentially decreased the cell viability of BRAF mutant WM266-4 cells ( Table 1 ). The selectivity ratio of CHL-1/ WM266-4 was more than 10-fold. The selectivity ratios of other inhibitors were smaller than 1.0. These results suggest that this screening system is suitable for the detection of BRAF-signaling inhibitors from microbial metabolites.
In this cell-based assay, we tested 3000 microbial extracts and identified the aimed inhibitory activity in the fermentation broth of an unidentified fungus. The active compounds were identified as malformin A1, A2 and C 6-9 by electrospray ionization tandem mass spectrometry (ESI-MS/MS) and the amino-acid analysis with Marfey's reagent N-(3-fluoro-4,6-dinitrophenyl)-L-alaninamide (FDAA). 10, 11 Next, we investigated the effects of malformin A1, A2 and C on the growth of BRAF-mutated and wild-type cells in this assay. The IC 50 values and selectivity ratio of BRAF-nonmutated cells/BRAF-mutated cells of malformin A1, A2 and C are shown in Table 2 . Malformin A2 and C preferentially inhibited the growth of BRAF mutant WM266-4 and SK-MEL-28 cells. The selectivity ratio of malformin A1 was lower than that of malformin A2 and C. The difference of amino-acid composition of these three compounds may reflect the difference in biological activity. Structure-activity relationship of malformin derivatives must be studied in the future.
During the investigation of the molecular target, we noticed that malformins changed the cell shapes drastically (Figure 1 ). WM266-4 shows flat and fibroblastic morphology (Figure 1a ), but most of the cells changed to round form after 3 h of treatment with malformin A1, A2 and C (Figures 1c-e) .
It was reported that microcystins and oscillamides, other cyclic peptide compounds, inhibit the protein phosphatases. 12, 13 Furthermore, tautomycin, a potent inhibitor of protein phosphatase 1 and 2A, also changed the cell morphology of WM266-4 cells as malformin did (Figure 1b) . These results suggest that malformins change cell morphology through protein phosphatase inhibition. To test this possibility, we next investigated the phosphorylation level of vimentin in malformin-treated NIH3T3 cells because it has been known that protein phosphatase 1 and 2A inhibitors induce vimentin overphosphorylation in situ. 14, 15 To determine whether the phosphorylation sites on vimentin were changed on treatment with malformins, we used site-specific phosphorylated vimentin antibodies, 4A4 and MO82 The concentrations of malformin A1, A2 and C needed to inhibit the cell growth in 50% of that in WM266-4, SK-MEL-28 and CHL-1 cells were determined as IC 50 . The selectivity of the inhibition was calculated as the ratio of the IC 50 value of malformin A1-, A2-and C-treated CHL-1 cells divided by that in WM266-4 or SK-MEL-28 cells. A cell-based screening method for the BRAF pathway inhibitors Y Asami et al antibodies that recognize phosphorylation at Ser55 and Ser82, respectively. 15 Tautomycin treatment induced the phosphorylation of Ser55 (4A4) and Ser82 (MO82) of vimentin. Likewise, malformin A1, A2 and C also induced phosphorylation of vimentin at Ser55 and Ser82 in NIH3T3 cells for 4 h incubation (Figure 2 ). These results suggest that malformin A1, A2 and C may affect protein phosphatases directly or indirectly in situ. There were several reports on the biological activity of malformins, [16] [17] [18] but this is the first observation that malformins affected protein phosphorylation of vimentin. Recently, malformin C induced the phosphorylation of cdc2. 19 Our finding is consistent with previous reports. [19] [20] [21] Further intensive studies on malformins may shed light on the pivotal events in the BRAF pathway of tumor cells. 
